Shots:
- The P-III (ASCEND) trial evaluated rocatinlimab (150 or 300mg, Q4W/Q8W) in ~2,600 atopic dermatitis pts who completed 24wks. in ROCKET trial program & continued for 32wks. in ASCEND, which will evaluate long-term safety & efficacy up to 104wks.
- Trial showed a favorable long-term safety profile (1EP) with low discontinuation rates due to AEs, consistent with prior studies
- 2EPs showed that adults achieving EASI 75 or vIGA-AD 0/1 at Wk. 24 in HORIZON or IGNITE trials & re-randomized, maintained a 1yr. benefit on rocatinlimab (Q4W/Q8W), with sustained improvements in skin clearance, itch & disease severity; data to be shared in future meeting or publication
Ref: Amgen | Image: Amgen and Kyowa Kirin| Press Release
Related News:- Kura Oncology and Kyowa Kirin Report the US FDA’s NDA Acceptance and Priority Review of Ziftomenib for Acute Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
